Brain glucose sensing, glucokinase and neural control of metabolism and islet function

E. O. Ogunnowo-Bada, N. Heeley, L. Brochard & M. L. Evans

Wellcome Trust-MRC Institute of Metabolic Science, IMS Metabolic Research Laboratories, University of Cambridge, Cambridge, UK

Introduction

In health, blood glucose is maintained within relatively narrow limits despite a variety of potential perturbations. This control is achieved by co-ordinated homeostatic physiological responses in pancreas, liver and skeletal muscle. Over recent years, it has become apparent that the brain also plays a pivotal role in controlling peripheral energy and metabolic homeostasis, including the control of blood glucose. Teleologically, this would appear to be logical given the dependence of the brain on a constant uninterrupted supply of glucose from the blood stream to fuel metabolism and support function.

A key part of this homeostatic process is that the brain needs to detect rapidly and accurately changes in blood glucose. Specialized brain fuel sensors monitor changes in ambient glucose. Importantly, in addition to local fuel sensing, the brain also receives information about changes in blood glucose from a number of other sources. Levels of circulating hormones such as insulin and glucagon respond to changes in blood glucose. Afferent neural inputs from peripheral sites – for example, vagal afferents from hepatic portal glucose sensors also feed in information.

The brain then utilizes this information to exert central and strategic control on a number of aspects of metabolism and energy balance. Triggering of counter-regulatory responses to falling glucose is perhaps the most obvious exemplar, but autonomic outflow from the brain also helps control hepatic glucose flux and facilitates glucose-stimulated insulin release from the pancreas.

A number of candidate mechanisms and indeed brain areas and cell types have been postulated as being important for local brain glucose sensing. We review below the current data, focusing particularly on the evidence for a role for the low-affinity hexokinase, glucokinase, in brain. In this review, we will: (i) first provide an outline of the evidence that brain glucose sensing is important for glucose homeostasis, (ii) give an overview of brain glucose-sensing mechanisms including those using glucokinase, (iii) then describe the current data supporting a role for brain glucokinase in the central control of glucose homeostasis and (iv) discuss how these processes may become altered in diabetes and related metabolic disorders.

Brain Glucose Sensing and Hypoglycaemia

The best-established homeostatic process that involves brain glucose sensing is the defensive response to hypoglycaemia. In health, a fall in blood glucose triggers a series of physiological responses aimed at limiting the fall and restoring euglycaemia (see Ref. [1] for review). Counter-regulatory neurohumoral responses include the cessation of endogenous insulin release followed by release of glucagon, catecholamines (including adrenaline from the adrenal medulla and increased autonomic outflow with a rise in circulating noradrenaline from spillover from sympathetic synapses), growth hormone and triggering of the hypophyseal–adrenal axis [adrenocorticotrophin (ACTH) and glucocorticoids]. These changes tend to limit glucose utilization and attempt to increase hepatic glucose output, not only by hormonal effects, but also probably through direct autonomic innervation of the liver. Counter-regulatory neurohumoral changes are associated with the generation of ‘adrenergic’ warning symptoms such as sweating, shaking and
heart palpatations. Importantly, hunger is also stimulated and consequent feeding will help restore and maintain euglycaemia.

If blood glucose falls sufficiently low, cognitive function starts to become impaired with a number of cognitive domains being affected – particularly those requiring attention, speed of response and judgement. Neuroglycopenic symptoms – for example, tingling of lips and irritability – are probable consequences of a fall in brain fuel. Because the brain is so dependent on circulating glucose to fuel metabolism and support function, it makes teleological sense for brain areas to be involved in monitoring blood glucose and triggering defences.

Evidence for a role for brain sensors in responses to hypoglycaemia came originally from studies using selective catheterization in dogs. Using this methodology, maintaining brain glucose during systemic hypoglycaemia resulted in a reduced neurohumoral reaction to the hypoglycaemic challenge, suggesting that it was the fall in glucose within the brain that triggered the processes leading to counter-regulation [2,3]. Elegant rat studies suggested an important role for the ventromedial nucleus of the hypothalamus (VMN), with local delivery of 2-deoxy glucose (2DG) to induce glucopenia, stimulating a counter-regulatory response. Also in keeping with a role for the VMN, lesioning of the VMN by stereotactic injection of ibotenic acid reduced counter-regulation. Similarly, maintenance of VMN glucose by locally delivered glucose during hypoglycaemia reduced counter-regulation [4–6]. Supporting a role for the brain stem, studies using 2DG or the alternative glucoprivic agent, 5-thioglucose, showed that hindbrain sensing of glucopenia was important [7–9]. Consistent with these data, a number of studies using more contemporary experimental manipulations have confirmed that a number of sites in both hypothalamus and brain stem are critical for triggering counter-regulatory responses. For example, mice lacking vesicular transporters for glutamate in VMN steroidogenic factor 1 (SF1) SF1 neurones have defective glucagon response to hypoglycaemia [10].

Importantly, in addition to brain sensing of hypoglycaemia, glucose sensors from the periphery, particularly portal vein sensors, may also play a significant role, especially for slowly developing hypoglycaemia [11–13], probably contributing information via vagal afferents into the dorsal vagal complex in the brain stem [14].

In diabetes, aggressive blood glucose lowering therapy increases risk of overshooting such that counter-regulatory responses become critical to preventing and/or limiting hypoglycaemia and restoring normal glucose. Described later, some patients develop deficits in counter-regulatory defences, putting them at greater risk of severe hypoglycaemia. A better understanding of the physiology of counter-regulation including how hypoglycaemia is sensed – whether glucokinase-mediated or not – and how these responses may become altered in diabetes could allow prevention of problematic hypoglycaemia.

**Brain Glucose Sensing and Pancreatic Insulin Secretion**

Over the last decade, the role of the brain in controlling hepatic glucose flux, at least in rodent models, has been firmly established. In particular, there is a clear circuity from the hypothalamus via vagal outflow to control glycaemia in response to locally detected changes in nutrients including glucose, and the circuity has been well-described elsewhere [15].

A similar role for the brain in modulating glucose-stimulated insulin secretion has also been suggested. Although the pancreas and indeed isolated islets and β-cells are capable of detecting changes in blood glucose and altering insulin secretion appropriately, the pancreas, including islets, is richly innervated by sympathetic (splanchnic), parasympathetic (vagus) systems and non-autonomic innervation. It has long been known that the taste, smell and even sight of food can trigger insulin release, referred to as the cephalic phase of insulin secretion [16]. A number of studies have shown that altering neural metabolism experimentally can change islet hormone release, including insulin [17]. Stimulation of the vagus nerve increases pancreatic insulin output [18–20], whereas the net effect of splanchnic nerve stimulation is to reduce insulin and increase glucagon output [21]. A number of studies using retrograde tracers such as modified pseudorabies virus injected into the pancreas have mapped out the central brain connections to pancreas, including areas that contain fuel-sensing neurones such as the dorsal vagal complex in the brain stem and key hypothalamic nuclei (reviewed in Ref. [17]).

Supporting a role for direct brain glucose sensing in the facilitation of insulin release, elegant studies in catheterized rats have shown that a small glucose bolus (insufficient to result in a systemic rise in glucose) given directly into the carotid artery directed towards brain induced a peripheral insulin response. This was associated with activation of the hypothalamic paraventricular and arcuate nuclei. [22,23]. Recent data suggest that, in addition to effects on insulin secretion, brain glucose sensing acting via pancreatic innervation may control β-cell mass [24].

**Brain Glucose Sensing and Feeding/Energy Homeostasis**

Although hypoglycaemia is a very potent stimulator of appetite, the role of brain glucose sensing at more physiological glucose levels remains unclear. Over 50 years ago, the glucostatic theory postulated that blood glucose levels were a physiological determinant of feeding. Suggested mechanisms were either in the initiation of eating, with small dips in blood glucose appearing to precede feeding and/or by the rise in blood glucose induced by feeding then acting as a satiety/meal termination signal.

Energy balance depends on intake but also on energy expenditure. Like other nutrients, glucose may also act centrally to generate thermogenesis [25], perhaps dependent on brain GLUT2-mediated glucose sensing (see below).

**Mechanisms of Brain Glucose Sensing**

For all of the above processes to occur, brain nutrient sensors need to be able to detect rapidly and accurately changes in blood glucose, presumably by detecting corresponding changes in ambient glucose within the brain. Glucose-sensing neurones were first described in the 1960s, with two populations
of neurones being either activated by glucose (glucose-excited - GE) or inhibited (originally referred to as glucose-sensitive but now globally labelled as glucose-inhibited – GI) [26,27]. GE and GI neurones have been identified in an increasing number of brain areas. Within the hypothalamus, both GE and GI neurons are found in the arcuate and paraventricular nuclei, with GI also particularly in the lateral hypothalamus and GE in the VMN [28]. GE and GI neurones are also found in the nucleus tracts tractus and area postrema in the brain stem [29,30]. It appears probable that different subgroups of GE and GI neurones exist, with some operating at higher glucose values (‘high GE’ and ‘high GI’ neurones).

Although most work has focused on the metabolic-sensing potential of neurones, it is clear that there is a close metabolic coupling between surrounding glial cells and neurones [31]. This may be important in glucose sensing also, for example with glucose being taken up by astrocytes and metabolized to lactate, which is then transported across into neurones. In this situation, glucose-sensing neurones would be responding to lactate rather than glucose per se.

There are probably a number of mechanisms by which GE and GI neurones respond to glucose and/or other fuels such as lactate. In broad terms, most postulated sensing mechanisms are ‘metabolic’, that is they depend on glucose-entering cells and being metabolized, with fuel sensing then detecting the process or products of that metabolism. Alternatively, sensing may use non-metabolic signals. For example, glucose sensing using the electrogenic signal generated by active glucose transport by sodium-coupled glucose co-transporter (SGLT) 1/3 has been described [32]. It is also possible that glucose sensing may occur without glucose entry into cells – for example by tandem pore potassium channels or perhaps even by taste receptors [33]. In this review, we have described briefly some of the metabolic sensors postulated to be important.

A number of research groups have examined the analogies between pancreatic β-cell and brain glucose sensing. Peculiar features of the β-cell that allow it to detect glucose (at least in the canonical pathway) include ATP-gated potassium (KATP) channels, the low-affinity glucose transporter GLUT2 and the low-affinity hexokinase, glucokinase.

The role of brain glucokinase is described later in this review. KATP channels are distributed widely in the brain, including in glucose-sensing areas. This wide distribution suggests that their role is broader than nutrient sensing – perhaps in protection of neurones against injurious insults. They have, however, been implicated in brain glucose sensing. Using a pharmacological approach, closing KATP channels by brain infusion of sulphonylureas attenuated responses to hypoglycaemia [34] and brain delivery of KATP channel openers increased hypoglycaemic counter-regulatory responses [35]. Mice deficient for the Kir6.2 subunit of KATP channels showed reduced responses in glucose-sensing neurones in the ventromedial hypothalamus and defective glucagon (but not adrenaline) responses to both hypoglycaemia and brain glucopenia. Of note, isolated islets from these mice studied ex vivo showed glucagon responses to glucose similar to those of wild-type mice [36].

Data suggest that hypothalamic levels of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) may act downstream of KATP channels to modulate glucagon responses to hypoglycaemia. Closing or opening KATP channels in the VMN resulted in increased or decreased VMN GABA levels, respectively, associated with suppression or amplification of glucagon and other counter-regulatory responses to hypoglycaemia [37,38]. Microperfusion of glucose into the VMN of rats suppressed glucagon and adrenaline responses to hypoglycaemia and altered VMN GABA with these effects of VMH glucose being blocked by GABA A antagonism [39].

The low-affinity transporter, GLUT2, has also been identified within brain regions. Using an elegant transgenic mouse model combining GLUT2 knockout (with re-expression of the alternative transporter GLUT1 in pancreatic β-cells to maintain insulin secretion), Thorens’ group found reduced glucagon responses to glucoprivation [40]. Glucagon responses to low glucose were restored by brain re-expression of GLUT2, but interestingly in glial rather than neuronal cells [41]. Parenthetically, the insulin-responsive transporter GLUT 4 and indeed insulin receptors have been identified in VMN GE and GI neurones although the significance for metabolic homeostasis remains to be fully determined [42].

A number of ‘non-β-cell’ sensing mechanisms dependent on intracellular metabolism of glucose have also been implicated in brain glucose sensing. Perhaps the best characterized is the cellular energy sensor AMP-activated protein kinase (AMPK), which is found widely in the brain, including in glucose-responsive cells [43]. Targeted genetic knockdown of AMPK in rat VMN suppressed glucagon responses to hypoglycaemia, whereas pharmacological activation of VMN AMPK amplified responses in rats with impaired counter-regulation [44,45].

**Distribution of Glucokinase in the Brain**

Approaches taken to identify the presence and distribution of glucokinase in the brain have largely looked for messenger RNA (mRNA) (RT-PCR and in situ hybridization) and activity assays measuring low-affinity glucose phosphorylation activity. Identifying glucokinase protein reliably has been more challenging, perhaps because of low levels of expression.

Studies using transgenic mice with human growth hormone expressed under the glucokinase promoter confirmed glucokinase expression in the brain, but detailed characterization of glucokinase-containing neurones was limited by a relatively low resolution [46]. This was also true for in situ hybridization studies with or without dual immunohistochemistry and RT-PCR work that identified some dual staining with candidate neuropeptides. However, full characterization was difficult [47,48]. Intriguingly, glucokinase mRNA has also been identified in tanycytes, raising the possibility that this population of glial cells are involved in metabolic sensing [49].

Stanley et al. have recently reported a comprehensive characterization of glucokinase-expressing cells in the brain [50]. To do so, they created a mouse line expressing cre-recombinase under control of the neuronal glucokinase promoter and crossed mice with a line expressing an EGFP-tagged ribosomal construct. This allowed them to examine the distribution of glucokinase in the brain and also to perform transcriptional
profiling of glucokinase-expressing cells. Using this model, glu-
cokinase was identified in hypothalamic and limbic regions of
the brain, with many of the areas having been identified (albeit
with less resolution) by previous studies. They also examined
and quantified responses to either 2DG or glucose and identified
activation measured by c-fos expression in glucokinase cells.

Perhaps the most insightful part of their work came from transcriptional profiling. Hypothalamic enrichment was identified for a number of neuropeptides that might have been predicted to be found in glucose-sensing cells [orexin, pro-opiomelanocortin (POMC), neuropeptide Y (NPY) and agouti-related peptide (AGRP)]. Dual immunohistochemistry confirmed that glucokinase was found in a subset of the corresponding cell populations with 36% of lateral hypothalamic orexin neurones (GI), 20% of POMC (GE) and 28% of NPY/AGRP (GI) neurones. Importantly, this emphasizes that there is likely to be heterogeneity within these cellular populations with some either using different fuel-sensing apparatus or perhaps not possessing the ability to sense glucose directly. Also of note, approximately one third of glucokinase-expressing cells in the brain identified by this approach were glial rather than neuronal.

There was a marked enrichment in growth-hormone-releasing hormone (GHRH)-containing neurones. Subsequent dual immunohistochemistry and patch clamp studies con-
firmed that the majority of GHRH neurones contained glucok
inase and that they were GI with activity increasing as blood
glucose fell. Growth hormone is a part of the counter-regulatory
hormonal response to hypoglycaemia, and prior to this work,
the mechanisms by which this was triggered were unclear. It
appears probable that this occurs via direct glucose sensing by
GHRH neurones utilizing glucokinase.

A paradox remains for β-cell-type adaptations such as glu-
cokinase and GLUT2, namely why brain would use low-affinity
mechanisms. Brain glucose values undoubtedly vary from
region to region, but are probably 10 to 30% of those observed
in the circulation. If so, one would predict that glucokinase
and GLUT2 would be largely inactive at ambient glucose levels,
and certainly so during hypoglycaemia. The question remains
unresolved. Although brain glucose sensors are clustered close
to circumventricular organs such as the median eminence
(hypothalamus) and area postrema (brain stem) where the
blood–brain barrier is deficient, there is currently little evidence
that this alters ambient glucose levels in the sensing areas per se.

Altering Brain Glucokinase Activity
Experimentally

Ex vivo, a number of studies using fresh brain slices and/or pri-
mary hypothalamic cultures have identified that glucokinase is
part of the sensing mechanism for at least a subset of GE and GI
hypothalamic neurones [42,51–53]. Knockdown of glucoki-
nase by interfering RNA in VMN preparations largely abolished
GE and GI glucose-sensing activities, whereas glucokinase
activation amplified both GE and GI responses. Extending
this work in vivo, infusion of GK activators into the VMN
reduced glucagon response to hypoglycaemia in rats. Similarly,
inhibiting glucokinase with alloxan or short hairpin RNA
(shRNA) knockdown increased responses – predominantly
adrenaline – to hypoglycaemic challenges [54]. Outside the
hypothalamus, glucokinase-dependent glucose sensing was also
identified in the medial amygdala nucleus with a population of
glucokinase-containing sensing neurones utilizing urocortin-
mediated connections to the basomedial hypothalamus exert-
ing a control loop to increase or decrease counter-regulatory
responses to hypoglycaemia [55]. Using third ventricle infusion
of pharmacological inhibitors of glucokinase, we were able to
stimulate feeding responses to glucoprivation [56]. This was
associated with activation of NPY and orexigenic cells [57].

One study has examined counter-regulatory hormone
responses in humans with glucokinase mutations leading to
‘MODY-2’ monogenic diabetes [58]. Glucagon responses to
hypoglycaemia were increased, although it is unclear whether
this was because of pancreatic or brain glucokinase in subjects
with a whole-body glucokinase activity alteration.

Interesting data examining the effect of the proapoptotic
protein, BCI-associated death promotor (BAD) may also reflect
a role for brain glucokinase in responses to hypoglycaemia.
In the β-cell, BAD alters glucose levels by altering insulin
secretion by at least two different mechanisms depending on
its phosphorylation status – an interaction with glucokinase
and by its proapoptotic actions. Acute genetic knockdown of
BAD in the brain impaired the glucagon response to systemic
glucoprivation in mice, although whether this was mediated
through altered brain GK activity remains unclear [59].

We have also examined whether brain glucokinase-mediated
glucose sensing is important in mediating insulin responses to
a rise in blood glucose [60]. We used intravenous glucose
tolerance tests in rats with delivery of test substances into
the base of the third ventricle. We first examined delivery
of glucose, reasoning that if brain sensing of glucose was
important for dealing with a systemic glucose load, that we
would see an increased efficiency of dealing with glucose
challenge. In keeping with this, we found that glucose handling
was improved, particularly early-phase insulin over the first
10 min after intravenous glucose delivery. Consistent with a
role for brain glucose sensing in facilitating insulin release,
early-phase insulin release was stimulated.

We then examined whether brain glucokinase contributed
to this observation, delivering glucokinase inhibitors into
the third ventricle of rats prior to and during intravenous
glucose bolus delivery. Again, in keeping with our hypothesis,
intracerebroventricular glucosamine or mannheptulose, an
alternative inhibitor, reduced glucose tolerance associated with
a decrease in insulin release over the first few minutes.

We have also examined the effects of pharmacological
inhibition of brain glucokinase on feeding responses. In keeping
with a role for brain glucokinase in central glucose sensing,
central delivery of glucosamine or mannheptulose rapidly
triggered robust feeding responses in rats [56].

Changes in Glucose Sensing in Diabetes
and Obesity?

A subset of patients with diabetes – particularly but not
only those with type 1 diabetes – develop deficiencies in
their counter-regulatory-defensive responses in the face of falling blood glucose. Neurohumoral responses are delayed and diminished, and the associated warning symptoms are also reduced. This altered physiology is associated clinically with a significantly increased risk of suffering from severe hypoglycaemia. Given the evidence for brain glucose sensing playing a key role in triggering counter-regulation (as discussed earlier), the unproven assumption is that this loss of counter-regulation or loss of warning symptoms is a consequence of altered glucose sensing and/or adaptations in the circuitry occurring very close to the site of glucose sensing.

The exact mechanisms remain to be fully determined and it is unclear whether glucokinase may play a role in this. For example, in juvenile rats, glucokinase expression within the VMN was increased after hypoglycaemia and associated with a shift in glucose responsiveness of GE neurons [61]. In contrast, we found no change in hypothalamic glucokinase expression following recurrent hypoglycaemia in rat brains, but rather an increase in hexokinase expression [62]. Regardless of whether involved in the pathoetiology, it is possible that targeting brain glucokinase might alter counter-regulatory responses to hypoglycaemia for good or bad. For example, one might predict a theoretical risk of reducing counter-regulation with glucokinase activation, a concern given that a number of pharmaceutical agents are in development for treating diabetes through activation of peripheral (β-cell and/or liver) GK.

Some reassurance comes from studies in humans in which a single dose of a glucokinase activator had no obvious central paracrine effect from altered insulin levels [63].

There is no compelling evidence for an effect of brain glucokinase on appetite and energy balance. As described above, we found that experimental inhibition of glucokinase in the rat brain stimulated glucoprivic feeding [56], but it is not clear how much overlap there is (if any) between feeding in response to a lack of glucose (a potential emergency situation) and general appetitive behaviour. We await more specific tools to manipulate brain glucokinase – perhaps targeted conditional transgenic murine models – to examine in a more definitive way whether brain glucokinase plays a broader role in energy metabolism.

Summary: Brain Glucokinase and Glucose Sensing

In summary, it appears probable that brain glucokinase is present in a variety of glucose-sensing cells – possibly both glial and neuronal. Intriguingly, it appears that this includes both GE cells – analogous to the pancreatic β-cell – but also GI neurones suggesting other downstream-mediating effects. It is tempting to speculate that GI neurones may be broadly analogous to pancreatic α-cells, but perhaps safest to assume that this all illustrates that brain glucose sensing shares some, but not all, features of those mechanisms identified elsewhere in the body.

Acknowledgements

Funding and support from Wellcome Trust, Medical Research Council including the Cambridge MRC Centre for Study of Obesity and Related Disorders (MRC-CORD), NIHR Cambridge Biomedical Research Centre, Diabetes UK (RD05/003059) and Yousef Jameel Fund.

Conflict of Interest

M. L. E. has acted on scientific advisory boards for Medronic, Roche, CellNovo, Abbott Diabetes Care, Ypsomed, Eli Lilly, NovoNordisk; has stock options in CellNovo; and has ongoing, recent or planned research collaborations with Medronic, Roche, Medingo, CellNovo, Oxford Medical Diagnostic and Senseonics. Other authors report no conflicts of interest.

References


